GenCore version 5.1.3

OM protein - protein search, using sw model

Run on: March 14, 2003, 03:18:01 ; Search time 1.88764 Seconds
(without alignments)
635.320 Million cell updates/sec

Title: US-09-698-781-17
Perfect score: 44
Sequence: 1 TLFPVLLFL 9

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	44	100.0	9	22	AAE02212	Human SGP28 peptid
2	44	100.0	71	20	AAY11989	Human 5' EST secre
3	44	100.0	245	22	AAM23992	Human EST encoded
4	44	100.0	245	22	AAM24000	Human EST encoded
5	44	100.0	258	22	AAE02211	Human full-length
6	35	79.5	68	22	AAM85541	Human immune/haema
7	35	79.5	101	22	AAB67466	Amino acid sequenc
8	35	79.5	467	17	AAW05754	Presenilin-1-1 A28
9	35	79.5	555	18	AAW89799	Staphylococcus aur
10	35	79.5	1325	21	AAG46049	Arabidopsis thalia
11	34	77.3	118	20	AAY11866	Human 5' EST secre
12	34	77.3	247	22	AAM78865	Human protein SEQ
13	34	77.3	247	22	AAB92912	Human protein sequ
14	34	77.3	247	22	AAB93064	Human protein sequ
15	34	77.3	247	23	AAE14683	Human transcriptio
16	34	77.3	247	23	AAU09500	Human kruppel homo
17	34	77.3	249	22	AAM79849	Human protein SEQ
18	34	77.3	392	22	AAG81957	S. epidermidis ope
19	34	77.3	398	23	ABP39879	Staphylococcus epi
20	34	77.3	405	20	AAW95085	S. aureus integral
21	33	75.0	15	22	AAG64335	Amidase family pro
22	33	75.0	59	21	AAG00585	Human secreted pro
23	33	75.0	59	23	ABP09865	Human ORFX protein
24	33	75.0	74	22	AAU14827	Novel bone marrow
25	33	75.0	81	22	ABB15544	Human nervous syst
26	33	75.0	89	23	ABB55012	Lactococcus lactis
27	33	75.0	95	22	AAG64334	Amidase family pro
28	33	75.0	123	21	AAB41632	Human ORFX ORF1396
29	33	75.0	245	22	AAG73778	Human colon cancer
30	33	75.0	261	21	AAY71214	Human irritable bo
31	33	75.0	267	21	AAB58455	Lung cancer associ
32	33	75.0	273	23	ABG66708	Human novel polype
33	33	75.0	279	20	AAY27686	Human secreted pro
34	33	75.0	350	23	ABB92039	Herbicidally activ
35	33	75.0	358	20	AAY36803	Chlamydia trachoma
36	33	75.0	365	20	AAY37139	Protein involved i
37	33	75.0	408	21	AAY84441	Amino acid sequenc
38	33	75.0	411	20	AAY34445	Porphorymonas ging
39	33	75.0	420	22	AAO12624	Human polypeptide
40	33	75.0	428	20	AAY34324	Porphorymonas ging
41	33	75.0	843	22	ABB11410	Human RNA-associat
42	33	75.0	843	22	AAM41212	Human polypeptide
43	33	75.0	857	23	ABP26367	Streptococcus poly
44	33	75.0	876	23	ABP30087	Streptococcus poly
45	33	75.0	888	22	AAM39426	Human polypeptide

ALIGNMENTS

RESULT 1
AAE02212
ID AAE02212 standard; peptide; 9 AA.
XX
AC AAE02212;
XX
DT 31-JUL-2001 (first entry)
XX
DE Human SGP28 peptide #1.
XX
KW Human; specific granule protein 28; SGP28; therapy; anticancer; colon;
KW prostate; cancer; prognosis; vaccine; major histocompatibility complex;
KW MHC; human leucocyte antigen; HLA-A2.
XX
OS Homo sapiens.
XX
PN WO200131343-A2.
XX
PD 03-MAY-2001.
XX
PF 27-OCT-2000; 2000WO-US29607.
XX
PR 28-OCT-1999; 99US-0162610.
XX
PA (UROG-) UROGENESYS INC.
XX
PI Hubert RS, Raitano AB, Afar DEH, Mitchell SC, Faris M;
PI Jakobovits A;
XX
DR WPI; 2001-308685/32.
XX
PT Detecting cancers, particularly of prostate and colon, from
PT overexpression of SGP28 protein, also methods for treating these

PT cancers e.g. by vaccination with the protein -
XX
PS Claim 18; Page 80; 102pp; English.
XX
CC The present invention relates to methods and compositions for the
CC diagnosis and therapy of prostate cancer which utilise human SGP28
CC (specific granule protein 28) gene and proteins. The method involves
CC detecting cancers, particularly of prostate and colon, from
CC overexpression of SGP28 protein. The expression of SGP28, which is an
CC extracellular protein is restricted to the prostate and ovary, and is
CC markedly up-regulated in prostate tumours. SGP28 sequence is used for
CC diagnosis (including in vivo imaging), staging, monitoring and prognosis
CC of prostatic and colon cancer, and for assisting selection of therapy.
CC Also SGP28-expressing cancers can be treated by administering a
CC composition or vaccine that contains a vector expressing an antibody
CC specific for SGP28 protein, nucleic acid encoding SGP28 protein or its
CC fragments, polypeptides encoded by SGP28 gene and SGP28-specific antibody
CC optionally conjugated to toxin or therapeutic agent. SGP28 gene product
CC is also used as source of therapeutic antisense or ribozyme agents, as
CC primers/probes for diagnosis or prognosis, to identify compounds that
CC inhibit calcium entry into prostatic cells, for recombinant production
CC of SGP28 peptides and for isolating related sequences. SGP28 protein and
CC its fragments are used to raise specific antibodies (Ab) and to identify
CC specific binding agents (potentially useful as therapeutic and
CC diagnostic agents) and also potential anticancer agents. The present
CC sequence is human SGP28 peptide. This sequence binds to the human MHC
CC (major histocompatibility complex) class I molecule (human leucocyte
CC antigen) HLA-A2.
XX
SQ Sequence 9 AA;

Query Match 100.0%; Score 44; DB 22; Length 9;
Best Local Similarity 100.0%; Pred. No. 7.8e+05;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TLFPVLLFL 9
|||||||||
Db 1 TLFPVLLFL 9

RESULT 2
AAY11989
ID AAY11989 standard; Protein; 71 AA.
XX
AC AAY11989;
XX
DT 18-JUN-1999 (first entry)
XX
DE Human 5' EST secreted protein SEQ ID No: 589.
XX
KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide; prostate;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS Homo sapiens.
XX
PN WO9906550-A2.
XX
PD 11-FEB-1999.
XX
PF 31-JUL-1998; 98WO-IB01232.
XX
PR 01-AUG-1997; 97US-0905144.
XX
PA (GEST) GENSET.
XX
PI Duclert A, Dumas Milne Edwards J, Lacroix B;
XX
DR WPI; 1999-153780/13.
DR N-PSDB; AAX40711.
XX
PT New isolated prostate-derived nucleic acids - used to develop
PT products which may have cytokine, immune regulatory, haematopoiesis
PT regulating, anti-inflammatory or tumour inhibition activity
XX
PS Claim 34; Page 672; 675pp; English.
XX
CC AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for
CC human secreted proteins expressed in prostate, and encode the proteins
CC given in AAY11716 to AAY11993 respectively. The proteins given represent
CC the signal peptide and an N-terminal fragment of a secreted protein. The
CC nucleic acid sequences can be used for producing secreted human gene
CC products. They can also be used to develop products for diagnosis and
CC therapy. The proteins obtained may have cytokine activity, cell
CC proliferation and differentiation activity, haematopoiesis regulating
CC activity, tissue growth regulating activity, reproductive hormone
CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.
CC The sequences can also be used for obtaining corresponding promoter
CC sequences. The nucleic acids encoding the signal peptides can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell.
XX
SQ Sequence 71 AA;.

Query Match 100.0%; Score 44; DB 20; Length 71;
Best Local Similarity 100.0%; Pred. No. 0.18;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TLFPVLLFL 9
|||||||||
Db 15 TLFPVLLFL 23

RESULT 3
AAM23992
ID AAM23992 standard; Protein; 245 AA.
XX
AC AAM23992;
XX
DT 12-OCT-2001 (first entry)
XX
DE Human EST encoded protein SEQ ID NO: 1517.
XX
KW Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
KW tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
KW diagnostics; forensic test; gene mapping; genetic disorder;
KW biodiversity; gene therapy; nutrition.
XX
OS Homo sapiens.
XX
PN WO200154477-A2.
XX
PD 02-AUG-2001.
XX
PF 25-JAN-2001; 2001WO-US02687.
XX
PR 25-JAN-2000; 2000US-0491404.
PR 17-JUL-2000; 2000US-0617746.
PR 03-AUG-2000; 2000US-0631451.
PR 15-SEP-2000; 2000US-0663870.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Zhou P, Qian XB, Wang Z, Chen R, Asundi V;
PI Cao Y, Drmanac RA, Zhang J, Werhman T;
XX
DR WPI; 2001-476164/51.
DR N-PSDB; AAH98651.
XX
PT Isolated polypeptide for treatment of diseases, diagnostics, raising

```
PT   antibodies and research use -
XX
PS   Claim 20; Page 1047-1048; 1275pp; English.
XX
CC   The present invention provides the protein and coding sequences of novel
CC   proteins from a variety of organisms, including human, dog, cat, horse,
CC   cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
CC   urchin and tomato. These were derived from expressed sequence tags (ESTs)
CC   from the organism of interest. They can be used in diagnostics,
CC   forensics, gene mapping, identification of mutations, to assess
CC   biodiversity and for nutritional purposes. The present sequence is a
CC   protein of the invention.
XX
SQ   Sequence   245 AA;

  Query Match             100.0%;  Score 44;  DB 22;  Length 245;
  Best Local Similarity   100.0%;  Pred. No. 0.66;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 TLFPVLLFL 9
           |||||||||
Db       2 TLFPVLLFL 10


RESULT 4
AAM24000
ID   AAM24000 standard; Protein; 245 AA.
XX
AC   AAM24000;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Human EST encoded protein SEQ ID NO: 1525.
XX
KW   Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
KW   tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
KW   diagnostics; forensic test; gene mapping; genetic disorder;
KW   biodiversity; gene therapy; nutrition.
XX
OS   Homo sapiens.
XX
PN   WO200154477-A2.
XX
PD   02-AUG-2001.
XX
PF   25-JAN-2001; 2001WO-US02687.
XX
PR   25-JAN-2000; 2000US-0491404.
PR   17-JUL-2000; 2000US-0617746.
PR   03-AUG-2000; 2000US-0631451.
PR   15-SEP-2000; 2000US-0663870.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Zhou P,  Qian XB,  Wang Z,  Chen R,  Asundi V;
PI   Cao Y,  Drmanac RA,  Zhang J,  Werhman T;
XX
DR   WPI; 2001-476164/51.
DR   N-PSDB; AAH98659.
XX
PT   Isolated polypeptide for treatment of diseases, diagnostics, raising
PT   antibodies and research use -
XX
PS   Claim 20; Page 1051-1052; 1275pp; English.
XX
CC   The present invention provides the protein and coding sequences of novel
CC   proteins from a variety of organisms, including human, dog, cat, horse,
CC   cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
CC   urchin and tomato. These were derived from expressed sequence tags (ESTs)
CC   from the organism of interest. They can be used in diagnostics,
CC   forensics, gene mapping, identification of mutations, to assess
CC   biodiversity and for nutritional purposes. The present sequence is a
CC   protein of the invention.
XX
SQ   Sequence   245 AA;

  Query Match             100.0%;  Score 44;  DB 22;  Length 245;
  Best Local Similarity   100.0%;  Pred. No. 0.66;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 TLFPVLLFL 9
           |||||||||
Db       2 TLFPVLLFL 10


RESULT 5
AAE02211
ID   AAE02211 standard; Protein; 258 AA.
XX
AC   AAE02211;
XX
DT   31-JUL-2001  (first entry)
XX
DE   Human full-length 36P1G3/SGP28 protein.
XX
KW   Human; 36P1G3 clone; specific granule protein 28; SGP28; therapy;
KW   prostate; colon; cancer; prognosis; vaccine; anticancer.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1..32
FT                   /label= Signal_peptide
FT   Protein         33..258
FT                   /note= "Human mature full-length 36P1G3/SGP28 protein"
FT   Modified-site   26..31
FT                   /note= "N-myristoylation site; This region is
FT                   specifically referred in claim 18"
FT   Modified-site   106..108
FT                   /note= "Protein kinase C phosphorylation site; This
FT                   region is specifically referred in claim 18"
FT   Modified-site   108..114
FT                   /note= "Tyrosine kinase phosphorylation site; This
FT                   region is specifically referred in claim 18"
FT   Modified-site   128..131
FT                   /note= "Casein kinase II phosphorylation site; This
FT                   region is specifically referred in claim 18"
FT   Domain          148..158
FT                   /note= "Extracellular protein SCP signature sequence"
FT   Modified-site   164..169
FT                   /note= "N-myristoylation site; This region is
FT                   specifically referred in claim 18"
FT   Domain          179..190
FT                   /note= "Extracellular protein SCP signature sequence"
FT   Modified-site   188..193
FT                   /note= "N-myristoylation site; This region is
FT                   specifically referred in claim 18"
FT   Modified-site   201..206
FT                   /note= "N-myristoylation site; This region is
FT                   specifically referred in claim 18"
FT   Modified-site   206..209
FT                   /note= "Casein kinase II phosphorylation site; This
FT                   region is specifically referred in claim 18"
FT   Modified-site   214..219
FT                   /note= "N-myristoylation site; This region is
FT                   specifically referred in claim 18"
FT   Modified-site   231..233
FT                   /note= "Protein kinase C phosphorylation site; This
FT                   region is specifically referred in claim 18"
FT   Modified-site   252..255
FT                   /note= "N-glycosylation site; This
FT                   region is specifically referred in claim 18"
XX
PN   WO200131343-A2.
XX
PD   03-MAY-2001.
```

XX
PF 27-OCT-2000; 2000WO-US29607.
XX
PR 28-OCT-1999; 99US-0162610.
XX
PA (UROG-) UROGENESYS INC.
XX
PI Hubert RS, Raitano AB, Afar DEH, Mitchell SC, Faris M;
PI Jakobovits A;
XX
DR WPI; 2001-308685/32.
DR N-PSDB; AAD06222.
XX
PT Detecting cancers, particularly of prostate and colon, from
PT overexpression of SGP28 protein, also methods for treating these
PT cancers e.g. by vaccination with the protein -
XX
PS Claim 16; Page 63; 102pp; English.
XX
CC The present invention relates to methods and compositions for the
CC diagnosis and therapy of prostate cancer which utilise human SGP28
CC (specific granule protein 28) gene and proteins. The method involves
CC detecting cancers, particularly of prostate and colon, from
CC overexpression of SGP28 protein. The expression of SGP28, which is an
CC extracellular protein is restricted to the prostate and ovary, and is
CC markedly up-regulated in prostate tumours. SGP28 sequence is used for
CC diagnosis (including in vivo imaging), staging, monitoring and prognosis
CC of prostatic and colon cancer, and for assisting selection of therapy.
CC Also SGP28-expressing cancers can be treated by administering a
CC composition or vaccine that contains a vector expressing an antibody
CC specific for SGP28 protein, nucleic acid encoding SGP28 protein or its
CC fragments, polypeptides encoded by SGP28 gene and SGP28-specific antibody
CC optionally conjugated to toxin or therapeutic agent. SGP28 gene product
CC is also used as source of therapeutic antisense or ribozyme agents, as
CC primers/probes for diagnosis or prognosis, to identify compounds that
CC inhibit calcium entry into prostatic cells, for recombinant production
CC of SGP28 peptides and for isolating related sequences. SGP28 protein and
CC its fragments are used to raise specific antibodies (Ab) and to identify
CC specific binding agents (potentially useful as therapeutic and
CC diagnostic agents) and also potential anticancer agents. The present
CC amino acid sequence is human full-length 36P1G3/SGP28 protein.
XX
SQ Sequence 258 AA;

Query Match 100.0%; Score 44; DB 22; Length 258;
Best Local Similarity 100.0%; Pred. No. 0.7;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TLFPVLLFL 9
|||||||||
Db 15 TLFPVLLFL 23

RESULT 6
AAM85541
ID AAM85541 standard; Protein; 68 AA.
XX
AC AAM85541;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:13134.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.

PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
DR N-PSDB; AAK58322.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Claim 11; SEQ ID NO 13134; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 68 AA;

Query Match 79.5%; Score 35; DB 22; Length 68;
Best Local Similarity 66.7%; Pred. No. 10;
Matches 6; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1 TLFPVLLFL 9
            | |||::||
Db      47 TAFPVIMFL 55
```

RESULT 7
AAB67466
ID AAB67466 standard; Protein; 101 AA.
XX
AC AAB67466;
XX
DT 15-MAY-2001 (first entry)
XX
DE Amino acid sequence of a calcium channel transport polypeptide.
XX
KW Calcium channel transport polypeptide; calcium trafficking;
KW neural disorder; HIV-induced dementia; immune system disorder;
KW rheumatoid arthritis; muscular disorder; muscle contractile dysfunction;
KW reproductive disorder; gastrointestinal disorder; pulmonary disorder;
KW cardiovascular disorder; arrhythmia; renal disorder;
KW proliferative disorder; cancer; lung carcinoma; breast cancer.
XX
OS Homo sapiens.
XX
PN WO200108635-A2.
XX
PD 08-FEB-2001.
XX
PF 27-JUL-2000; 2000WO-US20392.
XX
PR 28-JUL-1999; 99US-0145958.
PR 18-AUG-1999; 99US-0149446.
PR 14-MAR-2000; 2000US-0189064.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Ni J, Shi Y;
XX
DR WPI; 2001-138604/14.
DR N-PSDB; AAF55043.
XX
PT New isolated nucleic acid useful for diagnosing, detecting, or treating
PT or preventing diseases associated with anomalies in calcium trafficking
PT across the plasma membrane -

```
XX
PS   Claim 11; Page 258; 259pp; English.
XX
CC   The present sequence represents a calcium channel transport polypeptide.
CC   The polynucleotides, polypeptides, and antibodies are useful for
CC   preventing, treating, or ameliorating diseases associated with anomalies
CC   in calcium trafficking across the plasma membrane. They are used to
CC   diagnose, detect and treat or prevent diseases or conditions such as
CC   neural disorders (e.g. HIV-induced dementia), immune system disorders
CC   (e.g. rheumatoid arthritis), muscular disorders (e.g. muscle contractile
CC   dysfunction), reproductive disorders, gastrointestinal disorders,
CC   pulmonary disorders, cardiovascular disorders (e.g. arrhythmias), renal
CC   disorders, proliferative disorders, and/or cancerous diseases and
CC   conditions (e.g. lung carcinoma or breast cancer).
XX
SQ   Sequence   101 AA;

  Query Match             79.5%;  Score 35;  DB 22;  Length 101;
  Best Local Similarity   100.0%;  Pred. No. 16;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      2 LFPVLLF 8
          |||||||
Db     79 LFPVLLF 85


RESULT 8
AAW05754
ID   AAW05754 standard; Protein; 467 AA.
XX
AC   AAW05754;
XX
DT   23-JUL-1997  (first entry)
XX
DE   Presenilin-1-1 A285V mutation.
XX
KW   Presenilin-1; human; hPS1-1; hPS1-2; PS-2; integral membrane protein; AD;
KW   familial Alzheimer's disease; cerebral haemorrhage; schizophrenia;
KW   depression; antibody; gene expression modulator; therapy; mutein.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   285
FT                   /label= A285V
XX
PN   WO9634099-A2.
XX
PD   31-OCT-1996.
XX
PF   29-APR-1996;    96WO-CA00263.
XX
PR   31-JUL-1995;    95US-0509359.
PR   28-APR-1995;    95US-0431048.
PR   28-JUN-1995;    95US-0496841.
XX
PA   (HSCR-) HSC RES & DEV LP.
PA   (UTOR ) UNIV TORONTO GOVERNING COUNCIL.
XX
PI   Fraser PE,  Rommens JM,  St George-Hyslop PH;
XX
DR   WPI; 1996-497631/49.
XX
PT   New presenilin genes - useful for diagnosis, therapy and drug
PT   screening of familial Alzheimer's disease, cerebral disorders, etc.
XX
PS   Claim 3; Page -; 178pp; English.
XX
CC   AAW05736-W05760 represent mutated versions of the human presenilin-1-1
CC   protein (see AAW05733 for wild type sequence). AAW05734 represents a
CC   different wild type form of presenilin-1 that results from alternate
CC   splicing of the genomic DNA sequence. The presenilins are a family of
CC   highly conserved integral membrane proteins with a common structural
CC   motif, common alternate splicing patterns, and common mutational hot
CC   spot regions. Mutations in PS genes are implicated in familial
CC   Alzheimer's disease (AD) and possibly other diseases such as cerebral
CC   haemorrhage, schizophrenia, depression etc., so detection of mutations in
CC   the DNA encoding the wild type sequences can be used for diagnosis of
CC   these diseases. The wild type proteins, or vectors that express them or
CC   containing antisense sequences, antibodies selective for these mutant
CC   forms of the proteins and modulators of PS gene expression are
CC   potentially useful for treatment of AD etc. Transgenic animals are
CC   useful as models for drug screening. The antibodies can also be used e.g.
CC   for affinity purification and in immunoassays.
XX
SQ   Sequence   467 AA;

  Query Match             79.5%;  Score 35;  DB 17;  Length 467;
  Best Local Similarity   75.0%;  Pred. No. 80;
  Matches    6;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 TLFPVLLF 8
          ||||||::
Db    281 TLFPVLIY 288


RESULT 9
AAW89799
ID   AAW89799 standard; Protein; 555 AA.
XX
AC   AAW89799;
XX
DT   16-MAR-1999  (first entry)
XX
DE   Staphylococcus aureus protein SEQ ID #5247.
XX
KW   Computer readable medium; vaccine; S.aureus infection; immunodetection;
KW   cellulitis; eyelid infection; food poisoning; osteomyelitis; therapy;
KW   skin infection; surgical wound infection; scalded skin syndrome;
KW   toxic shock syndrome.
XX
OS   Staphylococcus aureus.
XX
PN   EP786519-A2.
XX
PD   30-JUL-1997.
XX
PF   07-JAN-1997;    97EP-0100117.
XX
PR   05-JAN-1996;    96US-0009861.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Barash SC,  Choi GH,  Dillon PJ,  Fannon MR,  Kunsch CA;
PI   Rosen CA;
XX
DR   WPI; 1997-374922/35.
XX
PT   Polynucleotide(s) and proteins derived from Staphylococcus aureus -
PT   stored on computer readable medium and used in the production of
PT   anti-S.aureus vaccines
XX
PS   Claim 23; Page 3252-3254; 3271pp; English.
XX
CC   This sequence represents a Staphylococcus aureus protein sequence of the
CC   invention. The DNA sequences encoding the S.aureus proteins are recorded
CC   on a computer readable medium, preferably selected from a floppy or hard
CC   disk, random access memory (RAM), read-only memory (ROM) or CD-ROM.
CC   Homology searches using the S.aureus DNA sequences allows putative
CC   functions to be assigned so that protein-encoding or regulatory regions
CC   of commercial, therapeutic or industrial importance can be obtained.
CC   Specifically, sequences which are likely to encode antigens have been
CC   identified and these polypeptides can be used in a vaccine composition
CC   against S.aureus infection. The polypeptides can also be used in a kit
CC   for the immunodetection of S.aureus in a sample. S.aureus is implicated
CC   in numerous human diseases, including cellulitis, eyelid infections, food
```

CC poisoning, osteomyelitis, skin and surgical wound infections, scalded
CC skin syndrome, toxic shock syndrome, etc. Organisms transformed with the
CC DNA sequences can be used for recombinant production of the polypeptides.
CC The new DNA sequences (and their fragments) are useful as primers or
CC probes for isolating homologues of any of the 5191 S.aureus DNA sequences
CC contained on the computer readable medium.
XX
SQ Sequence 555 AA;

Query Match 79.5%; Score 35; DB 18; Length 555;
Best Local Similarity 75.0%; Pred. No. 96;
Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy       2 LFPVLLFL 9
            :||||:||
Db      25 IFPVLMFL 32
```

RESULT 10
AAG46049
ID AAG46049 standard; Protein; 1325 AA.
XX
AC AAG46049;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 57890.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.

PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 79.5%; Score 35; DB 21; Length 1325;
Best Local Similarity 77.8%; Pred. No. 2.4e+02;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```
Qy       1 TLFPVLLFL 9
             |||:|| |
Db      72 TLFPLLLLL 80
```

RESULT 11
AAY11866
ID AAY11866 standard; Protein; 118 AA.
XX
AC AAY11866;
XX
DT 18-JUN-1999 (first entry)
XX
DE Human 5' EST secreted protein SEQ ID No: 466.
XX
KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide; prostate;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS Homo sapiens.
XX
PN WO9906550-A2.
XX
PD 11-FEB-1999.
XX
PF 31-JUL-1998; 98WO-IB01232.
XX
PR 01-AUG-1997; 97US-0905144.
XX
PA (GEST) GENSET.
XX
PI Duclert A, Dumas Milne Edwards J, Lacroix B;
XX
DR WPI; 1999-153780/13.
DR N-PSDB; AAX40588.
XX
PT New isolated prostate-derived nucleic acids - used to develop
PT products which may have cytokine, immune regulatory, haematopoiesis
PT regulating, anti-inflammatory or tumour inhibition activity
XX
PS Claim 34; Page 593; 675pp; English.
XX
CC AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for
CC human secreted proteins expressed in prostate, and encode the proteins
CC given in AAY11716 to AAY11993 respectively. The proteins given represent
CC the signal peptide and an N-terminal fragment of a secreted protein. The
CC nucleic acid sequences can be used for producing secreted human gene
CC products. They can also be used to develop products for diagnosis and
CC therapy. The proteins obtained may have cytokine activity, cell
CC proliferation and differentiation activity, haematopoiesis regulating
CC activity, tissue growth regulating activity, reproductive hormone
CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.
CC The sequences can also be used for obtaining corresponding promoter
CC sequences. The nucleic acids encoding the signal peptides can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell.
XX
SQ Sequence 118 AA;

Query Match 77.3%; Score 34; DB 20; Length 118;
Best Local Similarity 75.0%; Pred. No. 30;

```
  Matches    6;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 TLFPVLLF 8
           ::|||||||
Db     111 SIFPVLLF 118


RESULT 12
AAM78865
ID   AAM78865 standard; Protein; 247 AA.
XX
AC   AAM78865;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human protein SEQ ID NO 1527.
XX
KW   Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW   vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW   tissue growth factor; immunomodulatory; cancer; leukaemia;
KW   nervous system disorder; arthritis; inflammation.
XX
OS   Homo sapiens.
XX
PN   WO200157190-A2.
XX
PD   09-AUG-2001.
XX
PF   05-FEB-2001; 2001WO-US04098.
XX
PR   03-FEB-2000; 2000US-0496914.
PR   27-APR-2000; 2000US-0560875.
PR   20-JUN-2000; 2000US-0598075.
PR   19-JUL-2000; 2000US-0620325.
PR   01-SEP-2000; 2000US-0654936.
PR   15-SEP-2000; 2000US-0663561.
PR   20-OCT-2000; 2000US-0693325.
PR   30-NOV-2000; 2000US-0728422.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Drmanac RT,  Asundi V,  Zhou P,  Xu C,  Cao Y,  Ma Y;
PI   Zhao QA,  Wang D,  Wang J,  Zhang J,  Ren F,  Chen R,  Wang ZW;
PI   Xue AJ,  Yang Y,  Wejhrman T,  Goodrich R;
XX
DR   WPI; 2001-476283/51.
DR   N-PSDB; AAK51998.
XX
PT   Nucleic acids encoding polypeptides with cytokine-like activities,
PT   useful in diagnosis and gene therapy -
XX
PS   Claim 20; Page 3830; 6221pp; English.
XX
CC   The invention relates to polynucleotides (AAK51456-AAK53435) and the
CC   encoded polypeptides (AAM78323-AAM80302) that exhibit activity elating to
CC   cytokine, cell proliferation or cell differentiation or which may induce
CC   production of other cytokines in other cell populations. The
CC   polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC   peptide therapy. The polypeptides have various cytokine-like activities,
CC   e.g. stem cell growth factor activity, haematopoiesis regulating
CC   activity, tissue growth factor activity, immunomodulatory activity and
CC   activin/inhibin activity and may be useful in the diagnosis and/or
CC   treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC   inflammation.
CC   Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666
CC   (AAM80020) are omitted as the relevant pages from the sequence listing
CC   were missing at the time of publication.
XX
SQ   Sequence   247 AA;

  Query Match             77.3%;  Score 34;  DB 22;  Length 247;
  Best Local Similarity   75.0%;  Pred. No. 64;
  Matches    6;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 TLFPVLLF 8
           ::|||||||
Db     111 SIFPVLLF 118


RESULT 13
AAB92912
ID   AAB92912 standard; Protein; 247 AA.
XX
AC   AAB92912;
XX
DT   26-JUN-2001  (first entry)
XX
DE   Human protein sequence SEQ ID NO:11546.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS   Homo sapiens.
XX
PN   EP1074617-A2.
XX
PD   07-FEB-2001.
XX
PF   28-JUL-2000; 2000EP-0116126.
XX
PR   29-JUL-1999;   99JP-0248036.
PR   27-AUG-1999;   99JP-0300253.
PR   11-JAN-2000; 2000JP-0118776.
PR   02-MAY-2000; 2000JP-0183767.
PR   09-JUN-2000; 2000JP-0241899.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J;
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-318749/34.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602
PT   full-length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full-length cDNAs -
XX
PS   Claim 8; SEQ ID 11546; 2537pp + CD ROM; English.
XX
CC   The present invention describes primer sets for synthesising 5602
CC   full-length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC   AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence   247 AA;

  Query Match             77.3%;  Score 34;  DB 22;  Length 247;
  Best Local Similarity   75.0%;  Pred. No. 64;
```

```
  Matches    6;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 TLFPVLLF 8
            ::|||||
Db    111 SIFPVLLF 118


RESULT 14
AAB93064
ID   AAB93064 standard; Protein; 247 AA.
XX
AC   AAB93064;
XX
DT   26-JUN-2001  (first entry)
XX
DE   Human protein sequence SEQ ID NO:11878.
XX
KW   Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS   Homo sapiens.
XX
PN   EP1074617-A2.
XX
PD   07-FEB-2001.
XX
PF   28-JUL-2000; 2000EP-0116126.
XX
PR   29-JUL-1999;   99JP-0248036.
PR   27-AUG-1999;   99JP-0300253.
PR   11-JAN-2000; 2000JP-0118776.
PR   02-MAY-2000; 2000JP-0183767.
PR   09-JUN-2000; 2000JP-0241899.
XX
PA   (HELI-) HELIX RES INST.
XX
PI   Ota T,  Isogai T,  Nishikawa T,  Hayashi K,  Saito K,  Yamamoto J;
PI   Ishii S,  Sugiyama T,  Wakamatsu A,  Nagai K,  Otsuki T;
XX
DR   WPI; 2001-318749/34.
XX
PT   Primer sets for synthesizing polynucleotides, particularly the 5602
PT   full-length cDNAs defined in the specification, and for the detection
PT   and/or diagnosis of the abnormality of the proteins encoded by the
PT   full-length cDNAs -
XX
PS   Claim 8; SEQ ID 11878; 2537pp + CD ROM; English.
XX
CC   The present invention describes primer sets for synthesising 5602
CC   full-length cDNAs defined in the specification. Where a primer set
CC   comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC   to the complementary strand of a polynucleotide which comprises one of
CC   the 5602 nucleotide sequences defined in the specification, where the
CC   oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC   of an oligonucleotide comprising a sequence complementary to the
CC   complementary strand of a polynucleotide which comprises a 5'-end
CC   sequence and an oligonucleotide comprising a sequence complementary to a
CC   polynucleotide which comprises a 3'-end sequence, where the
CC   oligonucleotide comprises at least 15 nucleotides and the combination of
CC   the 5'-end sequence/3'-end sequence is selected from those defined in
CC   the specification. The primer sets can be used in antisense therapy and
CC   in gene therapy. The primers are useful for synthesising polynucleotides,
CC   particularly full-length cDNAs. The primers are also useful for the
CC   detection and/or diagnosis of the abnormality of the proteins encoded by
CC   the full-length cDNAs. The primers allow obtaining of the full-length
CC   cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC   AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC   AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC   represent oligonucleotides, all of which are used in the exemplification
CC   of the present invention.
XX
SQ   Sequence   247 AA;

  Query Match             77.3%;  Score 34;  DB 22;  Length 247;
  Best Local Similarity   75.0%;  Pred. No. 64;
  Matches    6;  Conservative    2;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 TLFPVLLF 8
            ::|||||
Db    111 SIFPVLLF 118


RESULT 15
AAE14683
ID   AAE14683 standard; Protein; 247 AA.
XX
AC   AAE14683;
XX
DT   09-AUG-2002  (first entry)
XX
DE   Human transcription factor and zinc finger protein (TFZN)-6.
XX
KW   Human; transcription factor and zinc finger protein; TFZN-6;
KW   cell proliferative disorder; arteriosclerosis; cirrhosis; cancer;
KW   developmental disorder; anaemia; epilepsy; autoimmune disorder;
KW   inflammatory disorder; acquired immune deficiency syndrome; AIDS;
KW   asthma; neurological disorder; Alzheimer's disease; Huntington's disease;
KW   transgenic animal; gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO200224895-A2.
XX
PD   28-MAR-2002.
XX
PF   21-SEP-2001; 2001WO-US29834.
XX
PR   22-SEP-2000; 2000US-234903P.
PR   30-OCT-2000; 2000US-244505P.
PR   08-DEC-2000; 2000US-254402P.
XX
PA   (INCY-) INCYTE GENOMICS INC.
XX
PI   Nguyen DB,  Yue H,  Gandhi AR,  Halafia AJA,  Walia NK,  Yao MG;
PI   Thornton M,  Ramkumar J,  Thangavelu K,  Lu Y,  Lee S,  Baughn MR;
PI   Tang YT,  Azimzai Y,  Kalafus DP,  Lu DAM;
XX
DR   WPI; 2002-394137/42.
DR   N-PSDB; AAD31106.
XX
PT   New polypeptides of human transcription factors and zinc finger
PT   proteins for diagnosing, treating or preventing disorders of
PT   neurological, immunological and cell proliferative disorders  -
XX
PS   Claim 1; Page 123; 137pp; English.
XX
CC   The present sequence is human transcription factor and zinc finger
CC   protein (TFZN)-6. TFZN protein is useful for screening an agonist/
CC   antagonist and a compound that specifically binds to it or modulates
CC   its activity. The polypeptide is also useful as an immunogen for
CC   preparing antibodies which are useful for diagnosing a disease associated
CC   with abnormal expression of TFZN, and for detecting and purifying the
CC   protein from a sample. Polynucleotide encoding TFZN is useful as a probe
CC   or a primer and for assessing toxicity of a test compound. A composition
CC   comprising the polypeptide, its agonist or an antagonist is useful for
CC   treating a disease or condition associated with decreased or increased
CC   expression of functional TFZN. Examples of disorders associated with
CC   abnormal expression of TFZN include cell proliferative disorders (e.g.
CC   arteriosclerosis, cirrhosis, psoriasis, cancer), developmental disorders
CC   (e.g. anaemia, epilepsy), autoimmune/inflammatory disorders (e.g.
CC   acquired immune deficiency syndrome (AIDS), asthma, Crohn's disease,
CC   Gout), neurological disorders (e.g. Alzheimer's disease, Huntington's
CC   disease, dementia). The polypeptide and polynucleotide of the invention
CC   are further useful for analysing a proteome of a tissue or a
CC   cell type. The polynucleotide is also useful for creating knockin
CC   humanised animals (pigs) or transgenic animals (mice or rats) to model
CC   human disease.
```

XX
SQ Sequence 247 AA;

Query Match 77.3%; Score 34; DB 23; Length 247;
Best Local Similarity 75.0%; Pred. No. 64;
Matches 6; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 TLFPVLLF 8
            ::||||||
Db     111 SIFPVLLF 118
```

Search completed: March 14, 2003, 05:40:28
Job time : 2.88764 secs